Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Patheon Board Recommends Rejecting JLL Offer | Contract Pharma

What are you searching for?

Sign in
Breaking News

Patheon Board Recommends Rejecting JLL Offer

Patheon's board of directors has recommended that shareholders reject JLL's recent $2 per share tender offer to take the company private.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Patheon‘s board of directors has recommended that shareholders reject JLL Partners‘ recent $2 per share tender offer to take the company private. The board, based on a unanimous recommendation of the special committee of independent directors, concluded that the offer undervalued Patheon’s shares. JLL has three nominees and the board; all declared conflicts of interest and did not vote on the recommendation. Patheon chief executive officer Wes Wheeler also abstained from voting.

The board’s recommendation noted that JLL’s offer sidestepped a $100 million payment it would need to gain 30% of the company’s Restricted Voting Shares. The board also noted that the $2 per share offer price is below the independent valuation the company recently received of $4.20 to $5.00 per Restricted Voting Share. That valuation was determined by BMO Capital Markets.

According to the company’s press release, several major shareholders in the company do not consider JLL’s offer strong enough and do not plan to accept the share price.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters